ES2905479T3 - Acidos grasos y su uso en la conjugación con biomoléculas - Google Patents

Acidos grasos y su uso en la conjugación con biomoléculas Download PDF

Info

Publication number
ES2905479T3
ES2905479T3 ES15732508T ES15732508T ES2905479T3 ES 2905479 T3 ES2905479 T3 ES 2905479T3 ES 15732508 T ES15732508 T ES 15732508T ES 15732508 T ES15732508 T ES 15732508T ES 2905479 T3 ES2905479 T3 ES 2905479T3
Authority
ES
Spain
Prior art keywords
hgdf15
ester
pharmaceutically acceptable
amide
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15732508T
Other languages
English (en)
Spanish (es)
Inventor
David Weninger Barnes
Ken Yamada
Chikwendu Ibebunjo
Alokesh Duttaroy
Louise Clare Kirman
Alexandra Marshall Bruce
Aimee Richardson Usera
Frederic Zecri
Jun Yuan
Changgang Lou
Aaron Kanter
Avirup Bose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53491695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2905479(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2905479T3 publication Critical patent/ES2905479T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/18—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon triple bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/285—Polyhydroxy dicarboxylic acids having five or more carbon atoms, e.g. saccharic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
ES15732508T 2014-06-23 2015-06-18 Acidos grasos y su uso en la conjugación con biomoléculas Active ES2905479T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462015862P 2014-06-23 2014-06-23
US201462082327P 2014-11-20 2014-11-20
US201562107016P 2015-01-23 2015-01-23
PCT/US2015/036328 WO2015200078A1 (en) 2014-06-23 2015-06-18 Fatty acids and their use in conjugation to biomolecules

Publications (1)

Publication Number Publication Date
ES2905479T3 true ES2905479T3 (es) 2022-04-08

Family

ID=53491695

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15732508T Active ES2905479T3 (es) 2014-06-23 2015-06-18 Acidos grasos y su uso en la conjugación con biomoléculas

Country Status (36)

Country Link
US (4) US10588980B2 (enExample)
EP (2) EP3157571B1 (enExample)
JP (5) JP6636959B2 (enExample)
KR (2) KR20230056796A (enExample)
CN (3) CN114133443A (enExample)
AP (1) AP2016009585A0 (enExample)
AU (1) AU2015280351C1 (enExample)
CA (1) CA2953480A1 (enExample)
CL (1) CL2016003281A1 (enExample)
CR (1) CR20160596A (enExample)
CU (1) CU24455B1 (enExample)
CY (1) CY1125006T1 (enExample)
DK (1) DK3157571T3 (enExample)
EA (1) EA039074B1 (enExample)
EC (1) ECSP17004665A (enExample)
ES (1) ES2905479T3 (enExample)
GT (1) GT201600263A (enExample)
HR (1) HRP20220152T1 (enExample)
HU (1) HUE057845T2 (enExample)
IL (1) IL248990B (enExample)
JO (1) JO3813B1 (enExample)
LT (1) LT3157571T (enExample)
MA (1) MA40278A (enExample)
MX (1) MX367520B (enExample)
MY (1) MY193993A (enExample)
PE (1) PE20171095A1 (enExample)
PH (1) PH12016502294B1 (enExample)
PL (1) PL3157571T3 (enExample)
PT (1) PT3157571T (enExample)
RS (1) RS62907B1 (enExample)
SG (2) SG10201912965TA (enExample)
SI (1) SI3157571T1 (enExample)
TN (1) TN2016000558A1 (enExample)
TW (3) TWI792596B (enExample)
UY (1) UY36186A (enExample)
WO (1) WO2015200078A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
AU2012240102C1 (en) 2011-04-08 2016-09-08 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
AP2016009011A0 (en) 2013-07-31 2016-01-31 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
AU2015356643B2 (en) 2014-12-04 2019-01-24 Novartis Ag Methods and compositions using Klotho variant polypeptides
AU2016209968B2 (en) * 2015-01-23 2018-11-29 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
EP3929293A3 (en) 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
US10633653B2 (en) 2015-08-14 2020-04-28 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
JP6946304B2 (ja) * 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
EP3408391A4 (en) 2016-01-31 2019-08-28 University of Massachusetts BRANCHED OLIGONUCLEOTIDES
CA3025251A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and uses thereof
KR101727506B1 (ko) * 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
EP3496758A4 (en) * 2016-08-12 2020-11-11 University of Massachusetts CONJUGATE OLIGONUCLEOTIDES
EP3571321A1 (en) 2017-01-23 2019-11-27 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
AU2018219283B2 (en) 2017-02-08 2022-05-19 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
KR20190139869A (ko) 2017-04-11 2019-12-18 리제너론 파마슈티칼스 인코포레이티드 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
EP3395793B9 (en) 2017-04-24 2021-09-29 IGM Group B.V. Process for the preparation of alpha-functionalized ketones
MA47392B1 (fr) * 2017-05-18 2021-09-30 Regeneron Pharma Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
CA3064590A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts Two-tailed self-delivering sirna and related methods
IL273550B2 (en) 2017-10-11 2025-09-01 Regeneron Pharma HSD17B13 inhibition in the treatment of liver disease in patients expressing the I148M variant of PNPLA3
ES2983433T3 (es) * 2017-12-22 2024-10-23 Novartis Ag Tratamiento de trastornos metabólicos con variantes de FGF21
KR20250154534A (ko) 2018-03-21 2025-10-28 리제너론 파마슈티칼스 인코포레이티드 17β-하이드록시스테로이드 데하이드로게나제 유형 13 (HSD17B13) iRNA 조성물 및 그것의 사용 방법
WO2019179494A1 (zh) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 取代的十五烷二酸化合物及药物组合物及其用途
MA52205A (fr) 2018-04-09 2021-02-17 Amgen Inc Protéines de fusion du facteur de différenciation de croissance 15
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
CA3106948A1 (en) 2018-08-10 2020-02-13 Novartis Ag Gfral extracellular domains and methods of use
WO2020033899A1 (en) 2018-08-10 2020-02-13 University Of Massachusetts Modified oligonucleotides targeting snps
US11279930B2 (en) 2018-08-23 2022-03-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
TWI869213B (zh) * 2018-09-19 2025-01-01 美商Ionis製藥公司 Pnpla3表現之調節劑
EA202191105A1 (ru) * 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP3887393A1 (en) 2018-11-26 2021-10-06 Novartis AG Lpl-gpihbp1 fusion polypeptides
WO2020150636A1 (en) 2019-01-18 2020-07-23 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
MY208040A (en) * 2019-04-23 2025-04-10 Lg Chemical Ltd Fusion polypeptide comprising fc region of immunoglobulin and gdf15
CN111909256A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
EP3999103A4 (en) 2019-07-19 2023-11-22 Inari Agriculture Technology, Inc. GENOMIC EDITING FOR ENHANCED HOMOLOGY-DIRECTED REPAIR
US12024706B2 (en) 2019-08-09 2024-07-02 University Of Massachusetts Modified oligonucleotides targeting SNPs
EP4025252A4 (en) 2019-09-03 2023-10-18 Arcturus Therapeutics, Inc. ASIALOGLYCOPROTEIN RECEPTOR-MEDIATED ADMINISTRATION OF THERAPEUTICALLY ACTIVE CONJUGATES
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
US20230210950A1 (en) 2019-10-04 2023-07-06 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
AU2020380587A1 (en) 2019-11-04 2022-01-06 Ferring B.V. Intranasal administration of merotocin for improving lactation
CN115397471A (zh) * 2019-11-26 2022-11-25 Dtx医药有限公司 包括核酸和半衰期延长基序的化合物
WO2021126990A1 (en) * 2019-12-16 2021-06-24 The Scripps Research Institute Oxytocin derivatives with improved properties
CN113597434B (zh) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
EP4090377A1 (en) * 2020-01-13 2022-11-23 Synaffix B.V. Conjugates of antibodies an immune cell engagers
EP4090379A1 (en) * 2020-01-13 2022-11-23 Synaffix B.V. Via cycloaddition bilaterally functionalized antibodies
EP4090376A1 (en) * 2020-01-13 2022-11-23 Synaffix B.V. Via cycloaddition bilaterally functionalized antibodies
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
TW202304500A (zh) 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物
AU2022278933A1 (en) * 2021-05-21 2023-12-07 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
IL309334A (en) 2021-06-23 2024-02-01 Univ Massachusetts Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
WO2023039522A1 (en) * 2021-09-10 2023-03-16 Guardian Therapeutics, Llc Fatty acid conjugates of nucleic acids
CN113582832B (zh) * 2021-09-13 2024-01-26 深圳瑞德林生物技术有限公司 一种长链二酸的制备方法
WO2023152698A1 (en) 2022-02-10 2023-08-17 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN114740105B (zh) * 2022-03-17 2023-11-07 重庆医药高等专科学校 一种脯氨酸和n-甲基脯氨酸的液相色谱分离检测方法及其应用
WO2023196754A2 (en) * 2022-04-08 2023-10-12 University Of North Texas Health Science Center At Fort Worth Treatment for reducing or preventing tissue fibrosis
CN114891086B (zh) * 2022-06-01 2024-03-26 恺佧生物科技(上海)有限公司 一种生物素标记的gdf15的复性方法
EP4565325A2 (en) * 2022-08-01 2025-06-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fatty acid-d-amino acid peptides conjugates as anaplerotic compounds for use in treating propionic acidemia, methylmalonic acidurias, and energy metabolic disorders
CN115575539B (zh) * 2022-10-12 2025-04-18 南方医科大学珠江医院 一种生物标本中短链脂肪酸及其羟基化衍生物的检测方法
CN116789764B (zh) * 2023-05-30 2025-01-03 北京悦康科创医药科技股份有限公司 一种抗冠状病毒多肽的制备方法
CN116466010B (zh) * 2023-06-15 2023-08-25 四川普锐特药业有限公司 一种用于脂质纳米粒中多种脂质组分定量检测的方法
WO2025049634A1 (en) * 2023-08-29 2025-03-06 Ganna Bio, Inc. Glycan conjugate compositions and methods

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043871A (en) * 1956-09-03 1962-07-10 Ruhrchemie Ag Production of heptadecanedicarboxylic acid-1, 17
EP0112344A1 (en) 1982-06-11 1984-07-04 National Research Development Corporation Amphipathic compounds
US4517105A (en) 1983-03-07 1985-05-14 Aluminum Company Of America Metalworking lubricant composition containing a novel substituted malonic acid diester
US4582927A (en) 1984-04-04 1986-04-15 Frito-Lay, Inc. Synthetic cooking oils containing dicarboxylic acid esters
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
EP0492628B1 (en) 1990-12-26 1996-07-03 Ricoh Company, Ltd Reversible thermosensitive coloring composition, recording medium, recording method and image display apparatus using the recording medium
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
WO1996018730A1 (en) 1994-12-15 1996-06-20 Human Genome Sciences, Inc. Prostatic growth factor
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
FR2735131B1 (fr) 1995-06-12 1997-08-22 Rech De Pathologie Appliquee S Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament
DE69637844D1 (de) 1995-06-22 2009-04-09 St Vincent S Hospital Sidney L Neues tgf-beta-ahnliches cytokin
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
CA2265444C (en) 1996-09-11 2008-11-18 Ortho-Mcneil Pharmaceutical, Inc. Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
DE69838986T2 (de) 1997-12-24 2009-01-08 Takeda Pharmaceutical Co. Ltd. Polypeptide, deren herstellung und verwendung
US6974684B2 (en) 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6297400B1 (en) 1999-07-02 2001-10-02 The Clorox Company Synthesis of a tetraamido macrocycle ligand from a novel diamidodiol
US20020045170A1 (en) 2000-04-06 2002-04-18 Wong Gordon G. Polynucleotides encoding novel secreted proteins
WO2001081928A1 (en) 2000-04-20 2001-11-01 St Vincent's Hospital Sydney Limited Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
MXPA03009566A (es) 2001-04-19 2004-12-06 Scripps Research Inst Metodos y composicion para la produccion de pares trna-aminoaciltrna sintetasa ortogonales.
US20030166903A1 (en) 2001-04-27 2003-09-04 Anna Astromoff Genes associated with vascular disease
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
MXPA05012465A (es) 2003-05-20 2006-01-30 Novartis Ag Heterociclos de nitrogeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma.
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
US20050191668A1 (en) 2004-01-14 2005-09-01 Lubing Zhou Methods of using peroxisome proliferator-activated receptor alpha target genes
DK2929891T3 (da) 2004-04-13 2020-05-11 St Vincents Hospital Sydney Ltd Fremgangsmåde til modulering af appetitten
WO2005099747A1 (en) 2004-04-14 2005-10-27 Medical Research Council Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
SI2426141T1 (sl) 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Postopek za preprečevanje ali zdravljenje infekcije z M tuberculosis
US20110319324A1 (en) 2005-05-27 2011-12-29 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP1971615B1 (en) 2005-11-30 2014-01-01 TaiMed Biologics, Inc. Lysme-based prodrugs of aspartyl protease inhibitors and processes for their preparation
DK1962886T4 (da) 2005-12-20 2022-05-02 Bristol Myers Squibb Co Stabile proteinformuleringer
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN101854947A (zh) 2007-08-16 2010-10-06 圣文森特医院悉尼有限公司 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法
WO2009042798A1 (en) 2007-09-26 2009-04-02 Cold Spring Harbor Laboratory Methods for treating fibrosis by modulating cellular senescence
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
DK2260053T3 (da) 2008-03-31 2014-06-23 Ferring Bv Oxytocin-analoger
JP5542832B2 (ja) 2008-10-24 2014-07-09 アイアールエム・リミテッド・ライアビリティ・カンパニー 生合成的に製造したピロリン−カルボキシ−リシンならびにピロリン−カルボキシ−リシンおよびピロリシン基の化学誘導体化を介する部位特異的タンパク質修飾
KR20110097807A (ko) * 2008-11-05 2011-08-31 에프. 호프만-라 로슈 아게 뉴로펩티드-2-수용체(ｙ-2ｒ) 작용제 및 이의 용도
EP2211182A1 (en) 2009-01-16 2010-07-28 Roche Diagnostics GmbH Method for the assessment of severity of liver cirrhosis
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
EP2261662B1 (en) * 2009-06-10 2014-01-22 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Novel synthetic blocking reagents
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP2521446A2 (en) 2010-01-06 2012-11-14 The University of North Carolina At Chapel Hill Fatty acid derivatives and analogs of drugs
CN101852804B (zh) 2010-03-29 2013-06-12 中国医学科学院病原生物学研究所 Gdf15蛋白的抗体的新用途
EP2563142A1 (en) * 2010-04-27 2013-03-06 Syngenta Participations AG Methods of controlling neonicotinoid resistant aphids
EP2563753B9 (en) 2010-04-27 2016-07-06 SynAffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
CA2800173C (en) 2010-05-21 2019-05-14 Ulrik Nielsen Bi-specific fusion proteins
GB201018518D0 (en) 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
AU2012240102C1 (en) 2011-04-08 2016-09-08 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
WO2012140647A2 (en) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Albumin binding probes and drug conjugates thereof
WO2013006656A2 (en) 2011-07-05 2013-01-10 The Regents Of The University Of California Appetite stimulating protein
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
EP2807266B1 (en) 2012-01-26 2020-01-15 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
CN104853781B (zh) 2012-11-30 2017-10-24 诺华股份有限公司 从含二硫化物的蛋白质制备缀合物的方法
HUE039848T2 (hu) 2012-12-21 2019-02-28 Hoffmann La Roche Peptidek oxitocin agonistákként
EP2934584B1 (en) 2012-12-21 2020-02-19 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
BR112015018104A2 (pt) 2013-01-30 2017-11-21 Ngm Biopharmaceuticals Inc polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
KR102476907B1 (ko) 2013-07-03 2022-12-13 하. 룬드벡 아크티에셀스카브 항-ｃｇｒｐ 항체를 사용하는 글루코오스 대사의 조절
WO2015006728A2 (en) 2013-07-11 2015-01-15 Usera Aimee Site-specific chemoenzymatic protein modifications
CA2918074A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure
US9683018B2 (en) 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
CA2918077A1 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
EP3024846A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic apelin derivatives for the treatment of heart failure
AP2016009011A0 (en) 2013-07-31 2016-01-31 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs
EA201691075A1 (ru) 2013-11-26 2016-09-30 Новартис Аг Способы оксимной конъюгации с кетон-модифицированными полипептидами
CN106102775A (zh) 2014-02-07 2016-11-09 效应物治疗公司 治疗纤维变性疾病的方法
KR101852804B1 (ko) 2014-05-01 2018-04-27 후지필름 가부시키가이샤 적외선 센서, 근적외선 흡수 조성물, 감광성 수지 조성물, 화합물, 근적외선 흡수 필터 및 촬상 장치
EP3139957A4 (en) 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3145552B1 (en) 2014-05-23 2020-03-04 Novartis AG Methods for making conjugates from disulfide-containing proteins
EA201790051A1 (ru) 2014-06-20 2017-04-28 Авео Фармасьютикалз, Инк. Лечение хронического заболевания почек и другого нарушения функции почек при помощи модулятора gdf15
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
CN106573955B (zh) 2014-06-23 2021-02-26 诺华股份有限公司 位点特异性蛋白质修饰
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3160496B1 (en) 2014-06-24 2021-03-03 Novo Nordisk As Mic-1 fusion proteins and uses thereof
PE20170771A1 (es) 2014-07-30 2017-07-04 Ngm Biopharmaceuticals Inc Composiciones y metodos de uso para tratar trastornos metabolicos
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
EA036985B1 (ru) 2014-10-31 2021-01-25 НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. Композиции и способы лечения метаболических расстройств
JP2018502908A (ja) 2014-12-22 2018-02-01 ノヴォ ノルディスク アー／エス アルファ‐１‐ アンチトリプシン（ａ１ａｔ）融合タンパク質及びその使用
AU2016209968B2 (en) 2015-01-23 2018-11-29 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
AU2016246602B2 (en) 2015-04-06 2020-11-19 Acceleron Pharma Inc. Single-arm type I and type II receptor fusion proteins and uses thereof
WO2016164503A1 (en) 2015-04-06 2016-10-13 Acceleron Pharma Inc. Alk7:actriib heteromultimers and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
WO2017066525A1 (en) 2015-10-14 2017-04-20 The Johns Hopkins University Protein bioconjugation method
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
EP3184106A1 (en) 2015-12-23 2017-06-28 Sanofi-Aventis Deutschland GmbH Growth differentiation factor 15 as biomarker for metformin
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
JP2019510739A (ja) 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Ｇｆｒａｌ受容体療法
US20170299608A1 (en) 2016-03-04 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
KR101727506B1 (ko) 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
JP2020517657A (ja) 2017-04-20 2020-06-18 ノヴォ ノルディスク アー／エス アルブミン融合タンパク質の精製方法
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
MA50233A (fr) 2017-09-10 2020-07-22 Novo Nordisk As Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
AU2020233876A1 (en) 2019-03-08 2021-09-23 Amgen Inc. Growth differentiation factor 15 combination therapy
US20230210950A1 (en) 2019-10-04 2023-07-06 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CN113597434B (zh) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN115916239A (zh) 2020-04-15 2023-04-04 治疗调适公司 用于靶向治疗性递送至骨的组合物和方法
WO2022092915A1 (ko) 2020-10-30 2022-05-05 가톨릭대학교 산학협력단 Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물

Also Published As

Publication number Publication date
TW202204384A (zh) 2022-02-01
CN107073130A (zh) 2017-08-18
TN2016000558A1 (en) 2018-04-04
WO2015200078A1 (en) 2015-12-30
CR20160596A (es) 2017-05-08
AU2015280351B2 (en) 2018-07-05
DK3157571T3 (da) 2022-02-21
KR20170020878A (ko) 2017-02-24
CU24455B1 (es) 2019-11-04
JP2017519024A (ja) 2017-07-13
EP3157571B1 (en) 2021-11-24
WO2015200078A8 (en) 2016-04-14
CL2016003281A1 (es) 2017-06-09
PE20171095A1 (es) 2017-08-07
MX367520B (es) 2019-08-26
TWI750725B (zh) 2021-12-21
UY36186A (es) 2016-01-29
US20160030585A1 (en) 2016-02-04
JP2023099133A (ja) 2023-07-11
CY1125006T1 (el) 2023-01-05
ECSP17004665A (es) 2018-11-30
HK1232160A1 (zh) 2018-01-05
MA40278A (fr) 2017-04-26
US11752211B2 (en) 2023-09-12
TW201613653A (en) 2016-04-16
JP6636959B2 (ja) 2020-01-29
BR112016028884A2 (pt) 2017-10-31
GT201600263A (es) 2019-07-19
JO3813B1 (ar) 2021-01-31
KR102559975B1 (ko) 2023-07-27
CN107073130B (zh) 2021-11-16
JP7650315B2 (ja) 2025-03-24
JP6823696B2 (ja) 2021-02-03
SG10201912965TA (en) 2020-02-27
HRP20220152T1 (hr) 2022-04-15
JP7051959B2 (ja) 2022-04-11
CN114133443A (zh) 2022-03-04
US10786576B2 (en) 2020-09-29
TW202039004A (zh) 2020-11-01
HUE057845T2 (hu) 2022-06-28
CA2953480A1 (en) 2015-12-30
PL3157571T3 (pl) 2022-03-28
PT3157571T (pt) 2022-02-14
RS62907B1 (sr) 2022-03-31
IL248990A0 (en) 2017-01-31
EP3157571A1 (en) 2017-04-26
CN114099693A (zh) 2022-03-01
MY193993A (en) 2022-11-07
EA039074B1 (ru) 2021-11-30
AU2015280351C1 (en) 2022-11-24
KR20230056796A (ko) 2023-04-27
AP2016009585A0 (en) 2016-11-30
IL248990B (en) 2019-09-26
TWI701048B (zh) 2020-08-11
SG11201609704TA (en) 2017-01-27
EA201692466A1 (ru) 2017-04-28
US20240066132A1 (en) 2024-02-29
EP3988170A1 (en) 2022-04-27
AU2015280351A1 (en) 2016-12-08
LT3157571T (lt) 2022-02-25
US10588980B2 (en) 2020-03-17
US20210000964A1 (en) 2021-01-07
JP2019206563A (ja) 2019-12-05
JP2020203934A (ja) 2020-12-24
TWI792596B (zh) 2023-02-11
CU20160189A7 (es) 2017-04-05
SI3157571T1 (sl) 2022-04-29
MX2016017395A (es) 2017-05-01
JP2022095757A (ja) 2022-06-28
PH12016502294A1 (en) 2017-02-13
US20180326079A1 (en) 2018-11-15
PH12016502294B1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
ES2905479T3 (es) Acidos grasos y su uso en la conjugación con biomoléculas
TWI613213B (zh) 作為雙重ｇｌｐ１／升糖素激動劑之艾塞那肽－４衍生物
ES2688367T3 (es) Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
ES2818109T3 (es) Modificaciones de proteínas específicas para un sitio
KR20150023690A (ko) 엑센딘-4 펩타이드 유사체
US20180009849A1 (en) Ghrelin analogues
HK1232160B (en) Fatty acids and their use in conjugation to biomolecules
HK40072273A (en) Fatty acids and their use in conjugation to biomolecules
BR112016028884B1 (pt) Conjugado compreendendo uma biomolécula ligada a um ácido graxo, seu uso, mistura, combinação, composição farmacêutica, e composto